Active, not recruiting
Phase 2
Long-Course Concurrent Chemoradiotherapy With Adebrelimab and Apatinib as Neoadjuvant Therapy for Locally Advanced/Low-Lying Rectal Cancer Requiring Sphincter Preservation
Condition(s) studied
Rectal Cancer Patients
Investigational drug(s) / intervention(s)
Long-course concurrent chemoradiotherapy combined with Adebrelimab and Apatinib
Long-course concurrent chemoradiotherapy combined with Adebrelimab and Apatinib: Long-course concurrent chemoradiotherapy regimen: 45-50 Gy administered in 25 fractions, with concurrent capecitabine 1650 mg/m²/day, bid on days 1-14, every 3 weeks as one cycle.
Adebrelimab: 1200 mg, intravenous infusion, on D1, once every 3 weeks.
Apatinib: 250 mg, orally, 5 days on and 2 days off; if the patient cannot tolerate the toxicity, the dose may be reduced to 125 mg once daily.
Each cycle is 21 days, with a total of 6 cycles of neoadjuvant therapy before surgery. Efficacy evaluation is performed after every 2 cycles. After 6 cycles of long-course concurrent chemoradiotherapy combined with Adebrelimab and Apatinib, the research team will reassess the patient. For resectable patients, surgery will be performed 4-6 weeks after neoadjuvant therapy. For patients who decline surgery or are deemed unfit for surgery after 6 cycles, if the investigator believes that continued treatment with Adebrelimab and Apatinib may still provide benefit, the treatment may be continued until
Study summary
To observe and evaluate the efficacy and safety of neoadjuvant long-course concurrent chemoradiotherapy combined with Adebrelimab and Apatinib Mesylate in the treatment of locally advanced rectal cancer and low-lying rectal cancer with sphincter-preservation demand.
Eligibility
Inclusion Criteria:
1. Age: 18 to 75 years, male or female;
2. Histologically or cytologically confirmed rectal cancer with measurable tumor lesion(s) (spiral CT or MRI scan ≥10 mm, meeting RECIST 1.1 criteria);
3. Clinical stage: rectal cancer cT3-4N0M0 or cT1-4N+M0, and low rectal cancer with a sphincter-preservation requirement (distance from the anal verge \<5 cm; stage T2N0M0);
4. Expected survival \>3 months;
5. ECOG PS score: 0-1;
6. No peritoneal metastasis or other distant metastasis;
7. No prior radiotherapy or immune checkpoint inhibitor therapy for rectal cancer;
8. Adequate function of vital organs as required (without the use of any blood components or cell growth factors during screening):
Absolute neutrophil count ≥1.5×10⁹/L; platelet count ≥80×10⁹/L; hemoglobin ≥8.5 g/dL; Thyroid-stimulating hormone (TSH) ≤1×ULN (if abnormal, T3 and T4 levels should also be assessed; patients with normal T3 and T4 levels may be enrolled); Bilirubin ≤1.5×ULN; ALT and AST ≤2.5×ULN; Serum creatinine ≤1.5×ULN;
9. Women of childbearing potential must have a negative pregnancy test (β-HCG) before starting treatment. Women of childbearing potential and men (who are sexually active with women of childbearing potential) must agree to use effective contraception consistently during treatment and for 6 months after the last dose;
10. Subjects voluntarily participate in the study and sign the informed consent form.
Exclusion Criteria:
1. Prior pelvic or abdominal radiotherapy;
2. Tumor expected to be unresectable after neoadjuvant therapy;
3. Pregnant or breastfeeding women, or women/ men of childbearing potential who refuse to use contraceptive measures;
4. History of other malignancies within the past 5 years, except for adequately treated cervical carcinoma in situ or cutaneous squamous cell carcinoma, or well-controlled basal cell carcinoma of the skin;
5. Uncontrolled symptomatic brain metastases, or poorly controlled psychiatric disorders, or severe intellectual or cognitive impairment;
6. Pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonitis, or severely impaired pulmonary function;
7. Active, known, or suspected autoimmune disease. Subjects with stable conditions not requiring systemic immunosuppressive therapy are eligible, e.g., type 1 diabetes, hypothyroidism requiring hormone replacement therapy, and skin conditions not requiring systemic treatment (e.g., vitiligo, psoriasis, and alopecia);
8. Congestive heart failure, uncontrolled arrhythmia, myocardial infarction within 6 months, unstable angina, stroke or transient ischemic attack, severe hypertension refractory to medication, or other conditions rendering the patient unable to tolerate surgery;
9. Severe active infection requiring intravenous antibiotic therapy during the screening period;
10. Known allergy to the study drug or any of its excipients, or a history of severe allergic reaction to other monoclonal antibodies;
11. Clinically significant bleeding symptoms or a clear bleeding tendency within 3 months prior to enrollment;
12. Hypertension that remains uncontrolled despite antihypertensive therapy prior to enrollment;
13. Patients with dysphagia;
14. Receipt of or planned receipt of live vaccines within 30 days prior to administration of adebrelimab;
15. Known history of HIV infection, or active hepatitis B or hepatitis C;
16. Inability to comply with the study protocol or to cooperate with follow-up;
17. Other conditions that the investigator considers inappropriate for participation in this trial.
Primary outcome measure(s)
- Complete Response Rate (cCR+pCR) — cCR assessed after neoadjuvant therapy; pCR assessed within 2 weeks post-surgery; assessed up to 6 months.
Proportion of patients achieving clinical complete response (cCR, no tumor residue by imaging and endoscopy) after neoadjuvant therapy or pathological complete response (pCR, no residual viable tumor cells in the tumor bed, %RVT=0) post-surgery.
Trial sites (1)
| Facility | City | Region | Status |
|---|
| No. 150, Haping Road, Nangang District, Harbin, Heilongjiang Province, China |
Harbin |
Heilongjiang |
|
More Harbin Medical University trials in China
Other trials for the same condition